NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting<
03 May 2022

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

A live webcast of the presentation will be available on Aura's “Investors & Media” page
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer<
03 May 2022

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules.
Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data<
27 Apr 2022

Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data

International pivotal trial expedited to potentially revolutionize hemodialysis treatment with an immediate and durable solution
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting<
27 Apr 2022

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF<
26 Apr 2022

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor
400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury<
25 Apr 2022

400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury

Decision from the first pre-specified futility analysis at 400 patients is expected in July
Cvrx reports first quarter 2022 financial and operating results<
25 Apr 2022

Cvrx reports first quarter 2022 financial and operating results

First quarter 2022 revenue of $4.1 million, a 43% increase over prior year
Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting<
11 Apr 2022

Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

We are encouraged by this data and look forward to further support the ongoing development of a uPARAPtargeting ADC in order to improve the outcome of our patients
Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke<
05 Apr 2022

Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke

ANA System Shown to Achieve High Rate of Complete Recanalization, Favorable 90 Day Outcomes
SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022<
31 Mar 2022

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022

Sparingvisionill be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.